FIGURE 2 3 Clinical applications of GLP-1RAs: comprehensive protection through multi-disease risk reduction 3.1 Cardiovascular protection GLP-1RAs confer substantial cardiovascular benefits that extend beyond glycemic control, primarily by reducing the incidence of major adverse cardiovascular events (MACE)
Eating slowly and chewing thoroughly taking at least 20-30 minutes per mealallows the satiety signals enhanced by these medications to register before overeating occurs
In our November review, Nutrition Insight highlights some of the months biggest stories, including breakthrough GLP-1 research and drug development, our discussion with AAK on the impact of supply chains on nutrition innovation, and Novonesis latest insights into microbiome-focused healthy longevity innovations
Indian companies are also developing a biosimilar for semaglutide where it seems that the patent will not be respected after 2026
When combined with lifestyle changes, medical guidance, and ongoing support, these therapies can help patients make sustainable progress toward their health goals